In ancient Syracuse, Damocles learned how power comes with peril when a single horsehair held a blade above his head.

At this week’s World Congress on Lung Cancer, Summit Therapeutics discovered combining trials to inflate your data comes with similar risks, especially when regulators are watching.

Sometimes being too clever by half creates the very problem you’re trying to solve.

In this critical review, we offer up our assessment of three phase 3 trials with three different outcomes… yet only one company is sitting in Barcelona this week knowing they’ve painted themselves into a regulatory corner of their own making.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers